A study to evaluate the quantification and pharmacologic selectivity of a 5HT6 PET ligand 11C-GSK215083 and to measure occupancies achieved at various doses of SB742457 in healthy volunteers

Trial Profile

A study to evaluate the quantification and pharmacologic selectivity of a 5HT6 PET ligand 11C-GSK215083 and to measure occupancies achieved at various doses of SB742457 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs GSK 215083 (Primary) ; Intepirdine
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top